C4 Therapeutics (CCCC) Upgraded to Buy: Here's Why

Earnings Estimate Revisions for C4 Therapeutics Analysts have been steadily raising their estimates for C4 Therapeutics. Over the past three months, the Zacks Consensus Estimate for the company has increased 16.2%. Unlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of 'buy' and 'sell' ratings for its entire universe of more than 4000 stocks at any point in time. Irrespective of mar ...